Study Information

Title: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL External
Status: Recruiting participants
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma
Interventions: Drug: TGR-1202; Drug: Ibrutinib
Institutions: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute
Health Topics: Non-Hodgkin Lymphoma

Contact Information


Beth Israel Deaconness Medical Center
Boston, MA 02215
Jon Arnason, MD
Dana Farber Cancer Institute
Boston, MA 02115
Matthew Davids, MD
617-632-5847
matthew_davids@dfci.harvard.edu